tiprankstipranks
Pfizer, BioNTech get FDA FTD for mRNA-based combination vaccine candidate
The Fly

Pfizer, BioNTech get FDA FTD for mRNA-based combination vaccine candidate

Pfizer (PFE) and BioNTech (BNTX) announced the companies have received Fast Track Designation from the U.S. FDA for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help prevent two respiratory diseases with a single injection. The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5, as well as mRNA strands encoding the hemagglutinin of four different influenza strains, recommended for the Northern Hemisphere 2022/23 by the World Health Organization.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PFE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles